Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of SY 5609, an Oral, Selective CDK7 Inhibitor, in Adult Patients With Select Advanced Solid Tumors

NCT04247126 is registered in ClinicalTrials.gov with Syros Pharmaceuticals as lead sponsor.

NCT NCT04247126
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04247126 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of SY 5609, an Oral, Selective CDK7 Inhibitor, in Adult Patients With Select Advanced Solid Tumors
Lead sponsor
Syros Pharmaceuticals
Phase
Phase 1
Overall status
Completed
Start date
January 23, 2020
Completion date
March 30, 2023
Enrollment
105 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumor, breast cancer, pancreatic cancer, small-cell lung cancer